AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
Acquiring Company
Merck
Acquired Company
Harpoon Therapeutics
Pembroke PinesSan FranciscoManufacturingBiotechnologyHealthcareHealth CareBiotechnologyPharmaceutical ManufacturingDescription
Merck has successfully acquired Harpoon Therapeutics for USD 680 million. This acquisition transforms Harpoon into a wholly owned subsidiary of Merck, enhancing its oncology pipeline with innovative cancer treatment technology. Harpoon's stock has exited Nasdaq as a result of the transaction.
Fundz sees it the moment Merck makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Harpoon Therapeutics?
Harpoon Therapeutics was acquired by Merck, based in Pembroke Pines. The deal was reported on September 24, 2026. Merck is privately held and operates in Manufacturing.
When did Merck acquire Harpoon Therapeutics?
Merck's acquisition of Harpoon Therapeutics was reported on September 24, 2026. Merck has successfully acquired Harpoon Therapeutics for USD 680 million. This acquisition transforms Harpoon into a wholly owned subsidiary of Merck, enhancing its oncology pipeline with innovative cancer treatment technology. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Harpoon Therapeutics do?
Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. It is privately held, operating in Biotechnology, and is based in San Francisco.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.